{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/27867"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/27867","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"Characterization of the bone marrow niche in Acute Myeloid Leukemia patients","abstract":"The bone marrow (BM) microenvironment (the niche) plays a critical role in regulating normal hematopoietic process and is dysregulated in bone and marrow-related malignancies such as Acute Myeloid Leukemia (AML). AML is an aggressive blood cancer affecting the myeloid lineage of the hematopoietic hierarchy, and occurs in mostly individuals of older age. The goal in recent years has been to prolong the survival of these elderly patients, who show morbidity and early induction mortality in the face of intensive treatments. Disease relapse also poses a major hurdle to overcome following the supposed eradication of the leukemic disease, as current disease monitoring strategies used to detect minimal residual disease (MRD) are insufficient and may vary between patients. Many turn to look at the hematopoietic niche for the development of non-cell autonomous AML therapies in the hopes of more targeted and tolerable therapies; however, these strategies focus solely on the elimination of leukemic cells, and remain ignorant to the deterioration of the niche stemming from the disease. As yet, studies on niche cells, including mesenchymal stem cells and their progenies, are riddled with discrepancies and remain challenging to perform as methods used in the field to investigate mesenchymal populations rely primarily on ex vivo assays which are subject to extraneous factors that can lead to biased interpretation. Here, we used an in vitro mesenchymal CFU assay to interrogate the BM niche of AML patients and identify aberrations to the diseased niche throughout progression of the leukemic disease. Our experimental findings showed that while BM adipocyte and osteoblast populations appeared to be equally impaired in AML patients, the reduction in adipogenesis capacity of BM mesenchymal cells seemed to be unique in relapsed patients. We further identified a novel adipogenesis-inducing molecule, Isoginkgetin, that can successfully correct this deficiency in AML BM-MSCs and promote BM adipogenesis in vivo.","abstract_html":"The bone marrow (BM) microenvironment (the niche) plays a critical role in regulating normal hematopoietic process and is dysregulated in bone and marrow-related malignancies such as Acute Myeloid Leukemia (AML). AML is an aggressive blood cancer affecting the myeloid lineage of the hematopoietic hierarchy, and occurs in mostly individuals of older age. The goal in recent years has been to prolong the survival of these elderly patients, who show morbidity and early induction mortality in the face of intensive treatments. Disease relapse also poses a major hurdle to overcome following the supposed eradication of the leukemic disease, as current disease monitoring strategies used to detect minimal residual disease (MRD) are insufficient and may vary between patients. Many turn to look at the hematopoietic niche for the development of non-cell autonomous AML therapies in the hopes of more targeted and tolerable therapies; however, these strategies focus solely on the elimination of leukemic cells, and remain ignorant to the deterioration of the niche stemming from the disease. As yet, studies on niche cells, including mesenchymal stem cells and their progenies, are riddled with discrepancies and remain challenging to perform as methods used in the field to investigate mesenchymal populations rely primarily on ex vivo assays which are subject to extraneous factors that can lead to biased interpretation. Here, we used an in vitro mesenchymal CFU assay to interrogate the BM niche of AML patients and identify aberrations to the diseased niche throughout progression of the leukemic disease. Our experimental findings showed that while BM adipocyte and osteoblast populations appeared to be equally impaired in AML patients, the reduction in adipogenesis capacity of BM mesenchymal cells seemed to be unique in relapsed patients. We further identified a novel adipogenesis-inducing molecule, Isoginkgetin, that can successfully correct this deficiency in AML BM-MSCs and promote BM adipogenesis in vivo.","abstract_has_math":false,"creators":["Henly, Charisa"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Biochemistry and Biomedical Sciences","school":null,"contributors":[],"advisors":["Bhatia, Mick"],"committee_chairs":[],"committee_members":[],"year":2022,"date_issued":"2022-11-17","date_published":"2022-11-17","updated_at":"2026-11-18T19:30:52Z","subjects":["acute myeloid leukemia","mesenchymal stem cells","bone marrow niche"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/8562"],"render_values":[{"text":"https://doi.org/10.71548/8562","href":"https://doi.org/10.71548/8562","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11375/27867","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"http://hdl.handle.net/11375/27867","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F27867","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Bhatia, Mick"]},{"key":"dc:contributor.department","label":"Department","values":["Biochemistry and Biomedical Sciences"]},{"key":"dc:creator","label":"Author","values":["Henly, Charisa"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2022-09-26T18:55:00Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2022-09-26T18:55:00Z"]},{"key":"dc:date.issued","label":"Date","values":["2022-11-17"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["acute myeloid leukemia","mesenchymal stem cells","bone marrow niche"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11375/27867","https://doi.org/10.71548/8562"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["The bone marrow (BM) microenvironment (the niche) plays a critical role in regulating normal hematopoietic process and is dysregulated in bone and marrow-related malignancies such as Acute Myeloid Leukemia (AML). AML is an aggressive blood cancer affecting the myeloid lineage of the hematopoietic hierarchy, and occurs in mostly individuals of older age. The goal in recent years has been to prolong the survival of these elderly patients, who show morbidity and early induction mortality in the face of intensive treatments. Disease relapse also poses a major hurdle to overcome following the supposed eradication of the leukemic disease, as current disease monitoring strategies used to detect minimal residual disease (MRD) are insufficient and may vary between patients. Many turn to look at the hematopoietic niche for the development of non-cell autonomous AML therapies in the hopes of more targeted and tolerable therapies; however, these strategies focus solely on the elimination of leukemic cells, and remain ignorant to the deterioration of the niche stemming from the disease. As yet, studies on niche cells, including mesenchymal stem cells and their progenies, are riddled with discrepancies and remain challenging to perform as methods used in the field to investigate mesenchymal populations rely primarily on ex vivo assays which are subject to extraneous factors that can lead to biased interpretation. Here, we used an in vitro mesenchymal CFU assay to interrogate the BM niche of AML patients and identify aberrations to the diseased niche throughout progression of the leukemic disease. Our experimental findings showed that while BM adipocyte and osteoblast populations appeared to be equally impaired in AML patients, the reduction in adipogenesis capacity of BM mesenchymal cells seemed to be unique in relapsed patients. We further identified a novel adipogenesis-inducing molecule, Isoginkgetin, that can successfully correct this deficiency in AML BM-MSCs and promote BM adipogenesis in vivo."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Master of Health Sciences (MSc)"]},{"key":"dc:title","label":"Title","values":["Characterization of the bone marrow niche in Acute Myeloid Leukemia patients"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Bhatia, Mick"],"dc:contributor.department":["Biochemistry and Biomedical Sciences"],"dc:creator":["Henly, Charisa"],"dc:date.accessioned":["2022-09-26T18:55:00Z"],"dc:date.available":["2022-09-26T18:55:00Z"],"dc:date.issued":["2022-11-17"],"dc:description.abstract":["The bone marrow (BM) microenvironment (the niche) plays a critical role in regulating normal hematopoietic process and is dysregulated in bone and marrow-related malignancies such as Acute Myeloid Leukemia (AML). AML is an aggressive blood cancer affecting the myeloid lineage of the hematopoietic hierarchy, and occurs in mostly individuals of older age. The goal in recent years has been to prolong the survival of these elderly patients, who show morbidity and early induction mortality in the face of intensive treatments. Disease relapse also poses a major hurdle to overcome following the supposed eradication of the leukemic disease, as current disease monitoring strategies used to detect minimal residual disease (MRD) are insufficient and may vary between patients. Many turn to look at the hematopoietic niche for the development of non-cell autonomous AML therapies in the hopes of more targeted and tolerable therapies; however, these strategies focus solely on the elimination of leukemic cells, and remain ignorant to the deterioration of the niche stemming from the disease. As yet, studies on niche cells, including mesenchymal stem cells and their progenies, are riddled with discrepancies and remain challenging to perform as methods used in the field to investigate mesenchymal populations rely primarily on ex vivo assays which are subject to extraneous factors that can lead to biased interpretation. Here, we used an in vitro mesenchymal CFU assay to interrogate the BM niche of AML patients and identify aberrations to the diseased niche throughout progression of the leukemic disease. Our experimental findings showed that while BM adipocyte and osteoblast populations appeared to be equally impaired in AML patients, the reduction in adipogenesis capacity of BM mesenchymal cells seemed to be unique in relapsed patients. We further identified a novel adipogenesis-inducing molecule, Isoginkgetin, that can successfully correct this deficiency in AML BM-MSCs and promote BM adipogenesis in vivo."],"dc:description.degree":["Master of Health Sciences (MSc)"],"dc:identifier.uri":["http://hdl.handle.net/11375/27867","https://doi.org/10.71548/8562"],"dc:language.iso":["en"],"dc:subject":["acute myeloid leukemia","mesenchymal stem cells","bone marrow niche"],"dc:title":["Characterization of the bone marrow niche in Acute Myeloid Leukemia patients"],"dc:type":["Thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:30:52Z"}